Newron Pharmaceuticals S.p.A. (FRA:NP5)

Newron Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	26.64	6.93	6.34	13.42	25.02	13.21
Short-Term Investments	16.56	2.89	6.26	9.35	9.58	18.04
Cash & Short-Term Investments	43.2	9.83	12.6	22.77	34.59	31.25
Cash Growth	254.41%	-22.01%	-44.68%	-34.17%	10.70%	-20.21%
Accounts Receivable	8.24	42.12	2.02	1.94	1.31	6.62
Other Receivables	4.68	4.94	3.16	3.03	2.74	-
Receivables	12.92	47.06	5.18	4.97	4.05	6.62
Prepaid Expenses	4.35	4.22	1.87	0.75	0.78	-
Total Current Assets	60.47	61.1	19.65	28.49	39.43	37.87
Property, Plant & Equipment	0.78	0.83	0.41	0.53	0.58	0.73
Other Intangible Assets	0	-	-	-	0	0.01
Other Long-Term Assets	0.15	1.97	5.81	8.18	10.48	12.58
Total Assets	61.39	63.91	25.87	37.2	50.49	51.2
Accounts Payable	1.09	2.47	2.02	1.91	1.5	1.27
Accrued Expenses	3.51	4.94	3.49	2.17	1.1	3.28
Current Portion of Long-Term Debt	33.78	13.41	22.28	-	-	-
Current Portion of Leases	0.12	0.14	0.18	0.17	0.15	0.15
Other Current Liabilities	1.59	2.55	0.97	0.79	0.9	2.19
Total Current Liabilities	40.08	23.51	28.93	5.04	3.65	6.89
Long-Term Debt	18.06	36.24	25.75	45.17	42.54	25.67
Long-Term Leases	0.61	0.67	0.21	0.33	0.39	0.52
Other Long-Term Liabilities	0.58	1.57	0.47	0.22	0.21	0.18
Total Liabilities	59.81	62.45	55.77	51.23	47.38	33.95
Common Stock	3.99	3.99	3.57	3.57	3.57	3.57
Additional Paid-In Capital	-	-	-	-	5.1	26.1
Retained Earnings	-5.14	10.69	-21.4	-22.81	-20.12	-26.16
Comprehensive Income & Other	2.73	-13.22	-12.08	5.21	14.55	13.74
Shareholders' Equity	1.58	1.46	-29.91	-14.03	3.11	17.25
Total Liabilities & Equity	61.39	63.91	25.87	37.2	50.49	51.2
Total Debt	52.57	50.47	48.42	45.66	43.08	26.35
Net Cash (Debt)	-9.37	-40.64	-35.82	-22.89	-8.49	4.91
Net Cash Growth	-	-	-	-	-	-77.98%
Net Cash Per Share	-0.44	-1.98	-2.01	-1.28	-0.48	0.27
Filing Date Shares Outstanding	19.96	19.96	17.85	17.85	17.85	17.85
Total Common Shares Outstanding	19.96	19.96	17.85	17.85	17.85	17.85
Working Capital	20.39	37.6	-9.27	23.45	35.77	30.98
Book Value Per Share	0.08	0.07	-1.68	-0.79	0.17	0.97
Tangible Book Value	1.58	1.46	-29.91	-14.03	3.11	17.24
Tangible Book Value Per Share	0.08	0.07	-1.68	-0.79	0.17	0.97

Source: S&P Global Market Intelligence. Standard template. Financial Sources.